Multiple organs express testin (TES), including the heart. Nevertheless, current understanding of the influence of TES on cardiovascular diseases, especially on cardiac hypertrophy and its etiology, is insufficient. This study investigated the influence of TES on cardiac hypertrophy and its etiology. Murine models with excessive TES expression specific to the heart were constructed with an adenoassociated virus expression system. Cardiac hypertrophy was stimulated through aortic banding (AB). The severity of cardiac hypertrophy was evaluated through molecular, echocardiographic, pathological, and hemodynamic examination. The findings of our study revealed that TES expression was remarkably suppressed not only in failing human hearts but also in mouse hearts with cardiac hypertrophy. It was discovered that excessive TES expression driven by an adeno-associated viral vector noticeably inhibited hypertrophy triggered by angiotensin II (Ang II) in cultivated cardiomyocytes from newborn rats. It was also revealed that TES knockdown via AdshTES caused the reverse phenotype in cardiomyocytes.
Elucidating the etiology of cardiac hypertrophy and its progression to congestive heart failure is necessary.
The human testin (TES) gene was originally identified in 1995
and was noted to have its highest expression in the testes, yet it is also widely expressed throughout other tissues. 6, 7 In humans, the TES gene is located in the FRG7G region on chromosome 7q31.2, which is believed to contain a tumour suppressor gene because of its lack of heterozygosity in multiple malignancies. 8, 9 The interest in TES mainly arises from the fact that it has been shown to be downregulated in an increasing number of human tumour types, in which its downregulation correlates with disease progression. [10] [11] [12] [13] [14] As a modular scaffold protein, TES contains a central PET (Prickle, Espinas, Testin) domain, a cysteine-rich region, and three LIM domains that compose the C-terminal half of TES. [14] [15] [16] The LIM domain was initially discovered in three transcription factors essential to development, Isl-1, Mec-3, and Lin-11. 17, 18 Later, various proteins with LIM domains were recognized that participate in various biological processes such as differentiation, the generation of malignancies, and the organization of the cytoskeleton. [19] [20] [21] The LIM domain of TES resembles that of other proteins, including FLH2, CRP3, and cysteine-rich domains 1 (Lmcd1), which serve as crucial modulators of cardiovascular diseases, especially cardiac hypertrophy, suggesting the potential participation of TES in cardiac hypertrophy. [22] [23] [24] Consequently, we hypothesized that TES could be a promising modulator of cardiac hypertrophy.
It was discovered in this study that the concentration of TES was suppressed in the hearts of patients suffering from dilated cardiomyopathy (DCM) as well as in cardiac hypertrophy models triggered by pressure overload. With the help of an adeno-associated virus expression system, it was discovered that pressure overload-stimulated cardiac hypertrophy was suppressed in mice with excessive TES expression. TES was able to directly interact with calcineurin and inhibit downstream reactions. Furthermore, calcineurin deactivation by cyclosporin A (CsA) clearly offset the amplified hypertrophic reaction stimulated by pressure overload in TES knockdown mice.
Our research suggests that TES is essential in the regulation of cardiac hypertrophy and can be used as a reliable target to treat cardiac hypertrophy.
| MATERIALS AND METHODS

| Reagents
Ang II and CsA were acquired from Sigma-Aldrich (St. Louis, MO, USA). A bicinchoninic acid (BCA) protein assay kit was acquired from Pierce (Rockford, IL, USA). Secondary antibodies conjugated with peroxidase (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were applied to observe the binding of the primary antibody (Table 1) . Fetal calf serum was procured from HyClone (Waltham, MA, USA). Cell cultivation reagents and other reagents were provided by Sigma-Aldrich.
| Human heart specimens
Samples of failing hearts were acquired from the left ventricles (LVs) of patients who suffered from DCM and had received treatments subsequent to heart transplantation ( 
| Animal model
Procedures related to animals were in conformity with the National were sacrificed, and the hearts, tibiae, and lungs were obtained. Tissues were weighed and evaluated to determine the lung weight/body weight (LW/BW, mg/g), heart weight/tibia length (HW/TL, mg/mm), and HW/BW (mg/g) ratios of the groups.
| Echocardiography and hemodynamic assessment
Echocardiography was conducted on mice anaesthetized with 1.5% isoflurane using a MyLab 30CV ultrasound machine (Biosound Esaote, Irvine, CA, USA) with a 10-MHz linear-array ultrasound transducer as described previously. [25] [26] [27] The LV dimensions were evaluated in the parasternal short-axis and long-axis views with a frame rate of 120 Hz. The LV end-diastolic diameter (LVEDD), ejection fraction (EF), LV end-systolic diameter (LVESD), and fractional shortening (FS) were determined through M-mode tracing with a sweeping velocity of 50 mm/s at the midpapillary muscle level. 
| Histological examination
Hearts were resected and immediately placed in a ten percent potassium chloride solution to ensure that they were halted in diastole. A saline solution was used to wash the hearts, which were subsequently put into ten percent formalin. Staining was performed with a 1:100 dilution of a-actinin. The staining procedures were identical to those used for the NRCMs after the deparaffinization step. The PCR used the primers in neonatal rat cardiomyocytes. The PCR used the primers in human. To overexpress TES, we used replication-defective adeno-associated viral vectors containing the entire rat TES cDNA coding region under the control of the cytomegalovirus promoter. An adeno-associated viral vector that encoded GFP served as the control. To perform TES knockdown, three rat TES constructs were acquired from SABiosciences. We then created three Ad-shTES adeno-associated viruses and selected the one that caused noticeable endogenous TES downregulation for further experiments.
Ad-shRNA served as a non-targeting control.
| Western blotting
Heart tissues and cultivated cardiac myocytes were lysed in RIPA buffer. A BCA protein assay kit was used for protein quantification. Protein extracts (50 μg) were separated with SDS-PAGE (Invitrogen, Carlsbad, CA, USA). The proteins were then transferred to a PVDF membrane (Millipore, Billerica, MA, USA) and incubated overnight with multiple primary antibodies at 4°C. After a 1 hour incubation with secondary antibodies at room temperature, the membranes were supplemented with ECL reagents (170-5061; Bio-Rad, Hercules, CA, USA) and observed with a FluorChem E imaging system (Cell Biosciences, Lake Franklin, NJ, USA). The expression of the proteins was normalized to that of GAPDH on an identical nitrocellulose membrane.
| Reverse transcription-PCR
Total mRNA was isolated from cultivated cells or LVs with TRIzol reagent (Invitrogen) and reverse transcribed into cDNA with a Transcriptor First Strand cDNA Synthesis Kit (Roche, Diagnostics, Mannheim, Germany). The relative expression of specific genes was evaluated using quantitative real-time PCR with SYBR Green (Roche).
The expression levels were normalized to GAPDH expression.
| Calcineurin assay
The activity of calcineurin phosphatase was evaluated in cell extracts with a Calbiochem Calcineurin Cellular Activity Assay Kit (Ref.
207007). The calcineurin activity was evaluated by examining the free phosphate released with or without EGTA buffer. Colorimetric examination was performed with a plate reader (Dynatech MR 5000, Melville, NY, USA) at a wavelength of 620 nm.
| Coimmunoprecipitation assays
For 
| Glutathione-S-transferase pull-down assay
Glutathione 
| Statistical analysis
Data are presented as the means ± SEM. Unpaired Student's t tests and two-way ANOVA with a Bonferroni posttest or a Tukey posttest were used to test for significant differences. P < 0.05 was recognized as significant. SPSS software (version 19.0; SPSS Inc., Chicago, IL, USA) was used to perform the statistical analyses.
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| Expression of TES is downregulated in human dilated cardiomyopathic hearts and murine hypertrophic hearts
To explore the potential influence of TES on cardiac hypertrophy, our study evaluated whether TES expression was changed in diseased hearts. Human dilated cardiomyopathic samples were obtained, and it was discovered that TES mRNA and protein expres- 
| TES negatively regulates Ang II-induced cardiomyocyte hypertrophy in vitro
To determine whether the changes in TES expression were in response to a hypertrophic irritant, our study examined whether TES was able to modulate the progression of cardiac hypertrophy by con- was clearly promoted in cardiomyocytes that were transduced with AdshTES ( Figure 2E) . However, the expression of these two markers was noticeably inhibited noticeably in cells transduced with AdTES Figure 3G ). Overall, the above findings suggested that excessive TES expression was able to inhibit the development of cardiac hypertrophy triggered by AB in vivo. Figure 4D and E). In summary, the above findings suggested that excessive TES expression was able to impair myocardial fibrosis triggered by pressure overload.
| TES overexpression attenuated fibrosis in pressure-overloaded hearts
| TES inhibited the calcineurin-NFAT pathway in murine hypertrophic hearts
This study next explored the mechanisms by which TES represses hypertrophy. Previous research has proven that the calcineurin-NFAT pathway participates in cardiac hypertrophy and that the muscle LIM protein is required for calcineurin-NFAT signalling at the sarcomeric Z disc. 28, 29 Consequently, our study examined whether TES modulates cardiac hypertrophy via the calcineurin-NFAT axis. It has previously been proven that stimulated calcineurin directly links with NFAT transcription factors, bringing about nuclear translocation and dephosphorylation of NFAT. Thus, our study evaluated cardiac NFAT translation triggered by pressure overload. It was discovered that the AB-mediated decrease in p-NFATc3 expression in the cytoplasm was noticeably promoted in the AVV9-TES group in comparison to that in the AVV9-GFP group. However, our study failed to observe any differences in p-NFATc1, p-NFATc2, and p-NFATc4 between the groups ( Figure 5A , C and D). Despite the fact that the AKT pathway and the MAPK pathway both modulate cardiac remodelling, our study failed to detect any differences in AKT or MAPK stimulation between the groups ( Figure 5B) . Overall, the above findings indicated that TESmodulated pathological cardiac hypertrophy relied, at least in part, on the modulation of the calcineurin-NFAT axis.
| TES directly interacts with calcineurin
Subsequently, we analysed the mechanism by which TES regulates calcineurin activity. In this study, we proved that NFAT nuclear Figure 7F ). The activity and structure of the heart was noticeably promoted in CsA-supplemented AB AAV9-shTES mice as indicated by echocardiographic parameters ( Figure 7G ). In general, the findings of our study suggested that CsA prevented cardiac hypertrophy development in TES knockdown mice by hindering the calcineurin-NFAT axis. Our findings also suggested that the protective influence of TES against cardiac hypertrophy was related to the modulation of the calcineurin-NFAT axis.
| DISCUSSION
Cardiac hypertrophy is a common reaction to multiple pathological irritants and ultimately causes heart failure, underlining the importance of identifying reliable targets through which to inhibit its progression. Our study proved that TES expression was inhibited in failing human heart specimens as well as in murine cardiac hypertro- Lmcd1 participates in the development of cardiac hypertrophy. 23 Hojayev and his colleagues proved that FHL2 was able to inhibit the pathological proliferation of the heart. 28 The above findings reliably indicate that TES is an essential modulatory of cardiac hypertrophy.
However, current understanding of the modulation of TES expression, particularly during the transition from cardiac hypertrophy to cardiac failure, is insufficient. Our study is the first to prove that TES is a reverse modulator of cardiac hypertrophy in cardiomyocytes, and it did so with an adeno-associated virus expression system. Nevertheless, further research is still needed elucidate the mechanism by which TES acts on the heart.
Multiple signalling pathways that include transcription factors, kinases, and G-protein coupled receptors participate in the modulation of heart growth. It has been proven that the calcineurin-NFAT axis is essential in regulating cardiac hypertrophy. 28, 29 NFATs are dephosphorylated by calcineurin in response to elevated intracellular calcium.
Calcineurin modulates the expression of genes in various tissues sensitive to calcium, including muscle, brain, and lymphocytes. NFAT transcription relies on dephosphorylation by calcineurin, which brings about nuclear translocation and the stimulation of targeted genes. 32, 33 It has recently been proven that the LIM protein in muscles is directly related to calcineurin and is crucial to the calcineurin-NFAT axis. 23, 28 However, little research has been conducted on the direct influence of TES on the calcineurin-NFAT axis. Our study is the first to prove that TES upregulation inhibits the calcineurin-NFAT axis in cardiac hypertrophy. Furthermore, GST pull-down assays, fluorescent confocal microscopy and Co-IP assays were performed to examine whether there was an interaction between TES and calcineurin. It was discov- In all, our study revealed a novel role for TES in the modulation of pathological cardiac hypertrophy through suppression of the calcineurin-NFAT axis. Our research is the first of its kind to prove the participation of TES in cardiac hypertrophy and to suggest that | 337
proteins consisting of LIM domains can act as a reservoir of signalling agents related to the preservation of cardiac homeostasis. We have discovered in this study that TES defends the heart in response to pressure overload, indicating that TES can serve as a promising diagnostic and therapeutic target for cardiac illness. However, further verification of the influence of TES on cardiac hypertrophy is necessary.
| CLINICAL PERSPECTIVES
This research offers in vitro and in vivo proof that excessive TES expression attenuates cardiac hypertrophy through suppression of the calcineurin-NFAT axis. We have verified that TES has an influence on cardiac hypertrophy in response to pressure overload and that TES is related to the calcineurin-NFAT axis in cardiac hypertrophy. The above findings are essential to elucidate the etiology of cardiac hypertrophy and to develop innovative strategies to treat cardiac hypertrophy by targeting TES.
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http://orcid.org/0000-0003-3782-9800 F I G U R E 7 Blocking calcineurin-NFAT signalling blunts cardiac hypertrophy in TES knockdown mice. A, TES protein expression level in mouse hearts after 1, 2, 4, or 8 weeks of AAV9-shTES injection (n = 4, *P < 0.05 vs AdshRNA group). B, Immunofluorescence staining of TES and a-actin in mouse hearts after 8 weeks of AAV9-shRNA or AAV9-shTES injection (n = 4). C, Statistical analysis of the ratios of LW/BW, HW/TL as well as HW/BW in indicated groups (n = 11-15). D, HE staining and WGA staining in mice 4 weeks subsequent to AB operation in indicated groups (n = 9-11). E, Statistical analysis for cross-sectional area (n = 100 cells). F, RT-PCR of β-MHC and ANP triggered via AB in indicated mice (n = 4). G, Echocardiographic parameters in indicated groups (n = 9-11)
